Evidence map›Paper›PMID 37007145›Full record

ArticleFrontiers in oncology2023

Identification of cuproptosis-based molecular subtypes, construction of prognostic signature and characterization of immune landscape in colon cancer.

Xu Wang, Xiaomin Zuo, Xianyu Hu, Yuyao Liu, Zhenglin Wang, Shixin Chan, Rui Sun, Qijun Han, Zhen Yu, Ming Wang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Xu WangDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Xiaomin ZuoDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Xianyu HuDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Yuyao LiuDepartment of Burns, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Zhenglin WangDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Shixin ChanDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Rui SunDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Qijun HanDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Zhen YuDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Ming WangDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Huabing ZhangThe First Affiliated Chuzhou Hospital of Anhui Medical University, Chuzhou, Anhui, China.
Wei ChenDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Anhui Medical University · CNFirst Affiliated Hospital of Anhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cuproptosis is a newly discovered form of cell death induced by targeting lipoacylated proteins involved in the tricarboxylic acid cycle. However, the roles of cuproptosis-related genes (CRGs) in the clinical outcomes and immune landscape of colon cancer remain unknown. Methods: We performed bioinformatics analysis of the expression data of 13 CRGs identified from a previous study and clinical information of patients with colon cancer obtained from The Cancer Genome Atlas and Gene Expression Omnibus databases. Colon cancer cases were divided into two CRG clusters and prognosis-related differentially expressed genes. Patient data were separated into three corresponding distinct gene clusters, and the relationships between the risk score, patient prognosis, and immune landscape were analyzed. The identified molecular subtypes correlated with patient survival, immune cells, and immune functions. A prognostic signature based on five genes was identified, and the patients were divided into high- and low-risk groups based on the calculated risk score. A nomogram model for predicting patient survival was developed based on the risk score and other clinical features. Results: The high-risk group showed a worse prognosis, and the risk score was related to immune cell abundance, microsatellite instability, cancer stem cell index, checkpoint expression, immune escape, and response to chemotherapeutic drugs and immunotherapy. Findings related to the risk score were validated in the imvigor210 cohort of patients with metastatic urothelial cancer treated with anti-programmed cell death ligand 1. Conclusion: We demonstrated the potential of cuproptosis-based molecular subtypes and prognostic signatures for predicting patient survival and the tumor microenvironment in colon cancer. Our findings may improve the understanding of the role of cuproptosis in colon cancer and lead to the development of more effective treatment strategies.

Indexed as

colon cancercuproptosisimmunotherapyprognosistumor microenvironment

Identifiers

PMID37007145
PMCPMC10064275
OpenAlexW4327729855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.